Traws Pharma 2025 Q2 Earnings 99.5% EPS Improvement and $2.73M Revenue Surge

Traws Pharma (TRAW) reported its Q2 2025 earnings on Nov 14, 2025, delivering a 99.5% improvement in EPS and a 4,694.7% revenue increase. The results exceeded expectations, driven by narrowed losses and strategic cost reductions. Management highlighted progress in antiviral programs and ongoing discussions with BARDA for stockpile inclusion, while noting short-term funding risks due to declining cash reserves.

Revenue

Traws Pharma’s total revenue surged to $2.73 million in Q2 2025, a 4,694.7% increase from $57,000 in Q2 2024. The Symbio segment accounted for the entire revenue, reflecting the company’s focus on its core antiviral therapies.

Earnings/Net Income

The company narrowed its net loss to $915,000 (a 99.3% reduction from $123.14 million in Q2 2024) and reported a loss per share of $0.11, a 99.5% improvement from $20.52. This marked a record high for Q2 net income in 14 years, underscoring operational efficiency gains.

Post-Earnings Price Action Review

The strategy of buying Traws Pharma shares on earnings days and holding for 30 days has historically yielded a 77.5% cumulative return over three years, outperforming the market. Recent price volatility—24% on the latest trading day but -23.32% month-to-date—reflects mixed investor sentiment. The closing price of $1.77 on Nov 13, 2025, provides a benchmark for assessing post-earnings performance.

CEO Commentary

Interim CEO Iain Dukes emphasized progress in antiviral programs, including Phase 2 trials for ratutrelvir and discussions with BARDA for TXM stockpiling. He noted deferred bird flu trials due to low H5N1 incidence and highlighted cash management challenges, with $6.4 million in reserves as of September 30, 2025.

Guidance

Traws Pharma aims to advance ratutrelvir trials, secure BARDA partnerships, and address cash runway concerns. No formal guidance was provided, but the company anticipates continued R&D expenses and seeks near-term financing to sustain operations.

Additional News

1. M&A Activity: Traws acquired a pyrrolidine antiviral IP for $2.6 million in September 2025, expanding its pipeline.

2. C-Level Changes: Robert Redfield (ex-CDC director) joined as Chief Medical Officer, strengthening clinical leadership.

3. Strategic Partnerships: Ongoing BARDA discussions for TXM stockpiling and potential collaborations for oncology assets (rigosertib/narazaciclib) remain priorities.

Article Polishing

Transitions between sections were refined, and punctuation adjusted for clarity. All numerical data and formatting were preserved. A

placeholder was inserted after the Price Action review to accommodate visual content.